Preclinical Trials On Synthetic Cannabinoid Drug For Covid-19 Suggest Benefits For Treating Lung Inflammation This week, Tetra Bio-Pharma announced that they had completed preclinical trials on the experimental synthetic cannabinoid drug, and the results suggest it could be helpful for reducing inflammation, scarring and damage in the lungs.